ADAP - Adaptimmune Therapeutics plc
| Previous Close | 4.9400 |
| Open | 4.9200 |
| Bid | 4.30 x 800 |
| Ask | 5.00 x 900 |
| Day's Range | 4.6800 - 4.9700 |
| 52 Week Range | 3.6000 - 14.6250 |
| Volume | 176,873 |
| Avg. Volume | 479,416 |
| Market Cap | 492.525M |
| Beta (3Y Monthly) | 1.50 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.91 |
| Earnings Date | Feb 27, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 13.57 |
- Simply Wall St.•13 days ago
Should You Worry About Adaptimmune Therapeutics plc’s (NASDAQ:ADAP) CEO Salary Level?
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! James Noble became the CEO of AdaptimmuneRead More...
- GlobeNewswire•13 days ago
Adaptimmune to Report Fourth Quarter / Full Year 2018 Financial Results and Business Update on Wednesday, February 27, 2019
PHILADELPHIA and OXFORD, United Kingdom, Feb. 07, 2019 -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will announce financial.
- Zacks•23 days ago
Adaptimmune Therapeutics PLC (ADAP) Upgraded to Buy: Here's What You Should Know
Adaptimmune Therapeutics PLC (ADAP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- Zacks•last month
Radius Exceeds 2018 Financial Guidance, Provides Updates
Radius (RDUS) exceeds its 2018 financial guidance, with full-year U.S. net sales of its lead drug Tymlos surpassing the upper range of $95-$98 million.
- Zacks•last month
Alnylam (ALNY) Reports Preliminary Onpattro Revenues for Q4
Alnylam (ALNY) reports preliminary revenues for Onpattro for the fourth quarter of 2018, and also provides other updates.
- GlobeNewswire•last month
Dose Escalation in Liver Cancer Study with ADP-A2AFP (AFP) SPEAR T-cells and Moving to Expansion Phase in ADP-A2M10 (MAGE-A10) Lung Cancer Study after Favorable Safety Reviews
PHILADELPHIA and OXFORD, United Kingdom, Jan. 07, 2019 -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that the.
- Simply Wall St.•2 months ago
What Percentage Of Adaptimmune Therapeutics plc (NASDAQ:ADAP) Shares Do Insiders Own?
The big shareholder groups in Adaptimmune Therapeutics plc (NASDAQ:ADAP) have power over the company. Generally speaking, as a company grows, institutions will increase their ownership. Conversely, insiders often decrease their Read More...
- GlobeNewswire•2 months ago
Adaptimmune Announces that Gwen Binder will leave in January 2019
PHILADELPHIA and OXFORD, United Kingdom, Dec. 12, 2018 -- Adaptimmune (Nasdaq: ADAP), a leader in T-cell therapy to treat cancer, today announced that Gwen Binder, PhD, Chief.
- GlobeNewswire•3 months ago
Recent Analysis Shows Bellicum Pharmaceuticals, NetEase, Nice, Match Group, SpartanNash, and Adaptimmune Therapeutics Market Influences — Renewed Outlook, Key Drivers of Growth
NEW YORK, Nov. 28, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- Thomson Reuters StreetEvents•3 months ago
Edited Transcript of ADAP earnings conference call or presentation 6-Nov-18 1:00pm GMT
Q3 2018 Adaptimmune Therapeutics PLC Earnings Call
Market Realist•3 months agouniQure Stock Rose 35.7% Yesterday—Here’s Why
On November 15, uniQure (QURE) stock closed at $30.93, which reflected a ~35.66% rise from its previous day’s close of $22.80.
- Simply Wall St.•3 months ago
What You Must Know About Adaptimmune Therapeutics plc’s (NASDAQ:ADAP) Financial Strength
Adaptimmune Therapeutics plc (NASDAQ:ADAP), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. However, the trade-off is ADAP Read More...
- Motley Fool•4 months ago
3 Beaten-Down Biotech Stocks: Can They Bounce Back?
See if these oncology-driven drugmakers have what it takes to recover from recent setbacks.
- Zacks•4 months ago
Adaptimmune Therapeutics Worldwide Enters Oversold Territory
Adaptimmune Therapeutics has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
- Simply Wall St.•5 months ago
Should You Be Holding Adaptimmune Therapeutics plc (NASDAQ:ADAP) Right Now?
If you’re interested in Adaptimmune Therapeutics plc (NASDAQ:ADAP), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock couldRead More...
Market Realist•6 months agoAdaptimmune Therapeutics Rose 21% in Week Ended August 24
On August 24, Adaptimmune Therapeutics (ADAP) stock closed at $10.25, which represents a ~21% growth from its previous week’s closing price of $8.48 on August 17.
